P. Guillem et al., Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus, INT J CANC, 88(6), 2000, pp. 856-861
Esophageal carcinoma includes squamous cell carcinoma and Barrett's adenoca
rcinoma. The latter usually develops from a premalignant lesion named Barre
tt's esophagus. MUC genes are known to be specifically expressed in the nor
mal, premalignant and malignant epithelia of various tissues. The aim of th
is study was to establish the pattern of MUC gene expression in the esophag
eal mucosa under normal conditions, and under pathological conditions such
as squamous cell carcinoma, Barrett's esophagus and adenocarcinoma. Samples
of esophageal control mucosa, metaplastic and malignant tissues were obtai
ned from 40 patients undergoing esophagectomy for squamous cell carcinoma (
n = 17), or Barrett's esophagus with adenocarcinoma (n = 23). In situ hybri
dization and northern blot were used with probes specific for the MUC1, MUC
2, MUC3, MUC4, MUC5AC, MUC5B, MUC6 and MUC7 genes to assess their expressio
n in these samples. Submucosal glands of control esophageal mucosa expresse
d MUC5B, whereas MUC1 and MUC4 were found in both control epithelium and sq
uamous cell carcinoma. MUC4 expression correlated with squamous cell differ
entiation. Barrett's adenocarcinoma exhibited various patterns of MUC gene
expression, the strongest being in the well-differentiated mucinous adenoca
rcinomas. Barrett's metaplasia was also associated with a specific MUC gene
expression pattern, since the gastric apomucin mRNAs, MUC5AC and MUC6, wer
e expressed in gastric metaplasia, and the intestinal apomucin mRNAs, MUC3,
MUC4 and mostly MUC2, in intestinal metaplasia. Residual expression of gas
tric apomucin mRNAs was found in intestinal metaplasia. From these results,
we conclude that MUC genes can be considered reliable phenotypic markers o
f the esophageal cell differentiation, thus providing new insight into the
development of Barrett's esophagus. Int. J. Cancer 88:856-861, 2000. (C) 20
00 Wiley-Liss, Inc.